Parkinson's Disease, Amantadine Hydrochloride Therapy and Dopa Metabolites

Authors

Dee Edward Silver, University of Iowa Hospitals
J. I. Routh, University of Iowa HospitalsFollow
A. L. Sahs, University of Iowa Hospitals
Richard Anderson, University of Iowa HospitalsFollow

Document Type

Research

Abstract

In an attempt to clarify the effect of amantadine hydrochloride therapy in Parkinson's disease, dopa metabolites were measured in the urine of 15 patients who were taking this medication. The results indicated that patients on amantadine therapy had lower urinary levels of epinephrine plus norepinephrine than either normal individuals or parkinsonian patients not receiving amantadine. Patients who developed livedo reticularis during amantadine therapy showed a small but significant increase in urinary dopamine levels and a similar decrease in dopac levels, when compared to other patients on amantadine who did not develop livedo reticularis.

Publication Date

June 1973

Journal Title

Proceedings of the Iowa Academy of Science

Volume

80

Issue

3

First Page

56

Last Page

58

Copyright

©1973 Iowa Academy of Science, Inc.

Language

en

File Format

application/pdf

Recommended Citation

Silver, Dee Edward; Routh, J. I.; Sahs, A. L.; and Anderson, Richard (1973) "Parkinson's Disease, Amantadine Hydrochloride Therapy and Dopa Metabolites," Proceedings of the Iowa Academy of Science, 80(3), 56-58.
Available at: https://scholarworks.uni.edu/pias/vol80/iss2/6